Parenteral gold therapy is an established treatment in rheumatoid arthritis. Thrombocytopenia is a recognised complication of this treatment, and in a small number of patients there may be life threatening haemorrhage. l 2 It is an unpredictable event and occurs in 1-3% of patients treated with gold.3 It has been shown that platelet size correlates with platelet function.4 5 The Coulter counter model S plus is a haematological analyser designed for routine laboratory use and provides a full blood count together with platelet parameters, including the mean platelet volume (MPV).6 To determine whether MPV could predict the onset of thrombocytopenia and possible haemorrhage this study examined the effects of gold on the MPV and the changes in MPV during thrombocytopenia.
Patients and methods
The Rheumatism Research Centre provides a monitoring service for some of the patients starting to receive disease modifying agents. The haematological records of all patients with rheumatoid arthritis receiving parenteral gold therapy were examined after introduction of the Coulter counter model S plus in 1982. Intramuscular chrysotherapy was instituted along standard lines, i.e., 10 mg weekly or 10 mg followed by 50 mg weekly until benefit, then 50 mg at fortnightly or three-weekly intervals. Complete data were obtained on 25 patients who were established on gold therapy for more than one Accepted for publication 13 June 1986. Correspondence to Dr P S Klimiuk 
counter model S plus haematological analyser has greatly facilitated the measurement of platelet size, expressing this parameter as the mean platelet volume. Moreover, the reproducibility and reliability have been validated. 6 The patterns of thrombocytopenia in our small group of patients are compatible with previous observations.8'l In particular our thrombocytopenic patients would fall into the group with an early precipitous thrombocytojenia, as described by Madhok and his colleagues.1 One of our patients was atypical in that the thrombocytopenia was precipitous, but she had been receiving gold therapy for 22 months. We also showed that all our patients with this form of thrombocytopenia were HLA-DR3. It would therefore appear, as a result of our observations and those of others,9 10 that HLA-DR3 is a very good marker for this type of toxicity.
The relation between MPV 
